Mastrorilli, V.; De Angelis, F.; Vacca, V.; Pavone, F.; Luvisetto, S.; Marinelli, S.
Xeomin®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury. Toxins 2023, 15, 248.
https://doi.org/10.3390/toxins15040248
AMA Style
Mastrorilli V, De Angelis F, Vacca V, Pavone F, Luvisetto S, Marinelli S.
Xeomin®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury. Toxins. 2023; 15(4):248.
https://doi.org/10.3390/toxins15040248
Chicago/Turabian Style
Mastrorilli, Valentina, Federica De Angelis, Valentina Vacca, Flaminia Pavone, Siro Luvisetto, and Sara Marinelli.
2023. "Xeomin®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury" Toxins 15, no. 4: 248.
https://doi.org/10.3390/toxins15040248
APA Style
Mastrorilli, V., De Angelis, F., Vacca, V., Pavone, F., Luvisetto, S., & Marinelli, S.
(2023). Xeomin®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury. Toxins, 15(4), 248.
https://doi.org/10.3390/toxins15040248